News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
329,617 Results
Type
Article (19731)
Company Profile (138)
Press Release (309748)
Section
Business (105255)
Career Advice (875)
Deals (18516)
Drug Delivery (93)
Drug Development (50681)
Employer Resources (79)
FDA (7652)
Job Trends (7724)
News (185636)
Policy (17307)
Tag
Academia (726)
Alliances (27778)
Alzheimer's disease (592)
Approvals (7635)
Artificial intelligence (96)
Bankruptcy (171)
Best Places to Work (5537)
Biosimilars (72)
Breast cancer (87)
Cancer (767)
Cardiovascular disease (76)
Career advice (708)
Cell therapy (112)
Clinical research (42115)
Collaboration (316)
Compensation (106)
COVID-19 (1080)
C-suite (86)
Data (799)
Diabetes (113)
Diagnostics (1731)
Drug pricing (99)
Earnings (38374)
Employer resources (73)
Events (47955)
Executive appointments (299)
FDA (8025)
Funding (224)
Gene therapy (105)
GLP-1 (525)
Government (1806)
Healthcare (5880)
Infectious disease (1137)
Inflammatory bowel disease (74)
Interviews (115)
IPO (7333)
Job creations (2431)
Job search strategy (646)
Layoffs (259)
Legal (4086)
Lung cancer (120)
Lymphoma (66)
Manufacturing (152)
Medical device (1954)
Medtech (1957)
Mergers & acquisitions (11308)
Metabolic disorders (385)
Neuroscience (807)
NextGen: Class of 2025 (2352)
Non-profit (904)
Northern California (823)
Obesity (247)
Opinion (179)
Patents (90)
People (33105)
Pharmaceutical (78)
Phase I (13161)
Phase II (17817)
Phase III (14331)
Pipeline (378)
Policy (78)
Postmarket research (1617)
Preclinical (4594)
Radiopharmaceuticals (157)
Rare diseases (175)
Real estate (3166)
Regulatory (12272)
Research institute (816)
Resumes & cover letters (138)
Southern California (756)
Startups (2006)
United States (7516)
Vaccines (223)
Weight loss (207)
Date
Today (13)
Last 7 days (235)
Last 30 days (920)
Last 365 days (17473)
2025 (798)
2024 (17684)
2023 (19645)
2022 (25871)
2021 (26654)
2020 (24892)
2019 (20061)
2018 (15587)
2017 (17255)
2016 (16203)
2015 (18802)
2014 (14787)
2013 (12553)
2012 (13482)
2011 (13817)
2010 (12738)
Location
Africa (406)
Asia (24630)
Australia (3168)
California (1872)
Canada (889)
China (221)
Colorado (77)
Connecticut (76)
Europe (50794)
Florida (284)
Illinois (189)
Indiana (137)
Japan (77)
Maryland (274)
Massachusetts (1588)
Minnesota (105)
New Jersey (719)
New York (537)
North Carolina (402)
Northern California (823)
Ohio (67)
Pennsylvania (440)
South America (605)
Southern California (756)
Texas (248)
Washington State (169)
329,617 Results for "redx pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program
Jazz Pharmaceuticals plc and Redx Pharma plc announced that the companies have signed a definitive agreement under which Jazz will acquire Redx’s KRAS inhibitor program.
February 7, 2024
·
6 min read
Business
Jazz Inks Potential $880M Deal with Redx to Buy KRAS Inhibitors
Jazz Pharmaceuticals is acquiring Redx Pharma’s KRAS inhibitor program including preclinical-stage drug candidates, with the companies working to advance assets through IND-enabling studies.
February 7, 2024
·
2 min read
·
Tyler Patchen
China
Big Pharma Rushes to China for Deal Prospecting Despite Regulatory Uncertainty
China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.
January 7, 2025
·
6 min read
·
Annalee Armstrong
Editorial
Pharma’s Q3 Was a Rollercoaster Ride. Let’s Do It Again Next Quarter
Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and wonderful world of biopharma.
November 15, 2024
·
3 min read
·
Annalee Armstrong
Deals
Redx and Jounce Announce Recommended Business Combination
Redx Pharma and Jounce Therapeutics, Inc. announce an unanimously recommended Business Combination of the two companies via a proposed all share merger transaction.
February 23, 2023
·
19 min read
Deals
Two Private Equity Firms Near Potential $3B+ Deal for Mitsubishi’s Pharma Unit: Reuters
Blackstone and Bain Capital are said to be among the final bidders for the Japanese company’s Mitsubishi Tanabe Pharma, sources told Reuters Friday.
December 13, 2024
·
1 min read
·
Annalee Armstrong
Business
The Biggest Pharma Share Moves of the Year So Far
Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share price. Other companies have not been so lucky.
November 27, 2024
·
9 min read
·
Annalee Armstrong
MASH
Boston Pharma Carves Out Monthly Treatment Niche in MASH With Strong Phase II Data
Boston Pharma’s once-monthly injection efimosfermin alfa offers a convenient dosing option for MASH patients while also achieving promising rates of fibrosis and MASH improvement, according to a Phase II readout.
November 18, 2024
·
2 min read
·
Tristan Manalac
Deals
Jounce Slashes 57% of Staff, Drops Assets in Stock Merger with Redx
One day after revealing a restructuring initiative, Jounce Therapeutics announced it plans to merge its business in an all-stock deal with clinical-stage biotech Redx Pharma.
February 23, 2023
·
1 min read
·
Rosemary Scott
Rare diseases
Facing a Dearth of Big Pharma Interest, Rare Disease Players Get Creative to Fund R&D
A handful of billion-dollar deals in the rare disease space highlights the uptick in Big Pharma’s investment, but it’s still extremely low compared to the money flowing to more common indications.
November 20, 2024
·
7 min read
·
Heather McKenzie
1 of 32,962
Next
